Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction

American Heart Journal

Volumn 164, Issue 6, 2012, Pages 846-855

  Christian, Jennifer B ^a   Finkle, John K ^a   Ky, Bonnie ^b   Douglas, Pamela S ^c   Gutstein, David E ^d   Hockings, Paul D ^e   Lainee, Pierre ^f   Lenihan, Daniel J ^g   Mason, Jay W ^h   Sager, Philip T ⁱ   Todaro, Thomas G ^j   Hicks, Karen A ^k   Kane, Robert C ^k   Ko, Hon Sum ^k   Lindenfeld, Joann ^l   Michelson, Eric L ^f   Milligan, James ^f   Munley, Jiefen Y ^f   Raichlen, Joel S ^f   Shahlaee, Amir ^k   Strnadova, Colette ^m   Ye, Brenda ^k   Turner, J Rick ⁿ   more..

^a GLAXOSMITHKLINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e ASTRAZENECA R AND D   (Sweden)

^f ASTRAZENECA   (United Kingdom)

^g VANDERBILT UNIVERSITY   (United States)

^h UNIVERSITY OF UTAH   (United States)

ⁱ Sager Consulting Partners   (United States)

^j Sager Consulting Partners ^*  (United States)

^k CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^l UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^m HEALTH CANADA   (Canada)

ⁿ IQVIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); DIAGNOSTIC ACCURACY; DOPPLER ECHOCARDIOGRAPHY; DRUG DEVELOPMENT; DRUG INDUCED DISEASE; DRUG SURVEILLANCE PROGRAM; ECHOCARDIOGRAPHY; HEALTH CARE COST; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART SCINTISCANNING; HUMAN; IMAGE QUALITY; INTERMETHOD COMPARISON; MYOCARDIAL DISEASE; POINT OF CARE TESTING; PRIORITY JOURNAL; RELIABILITY; REPRODUCIBILITY; SCINTIANGIOGRAPHY; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

EID: 84870291817     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2012.09.001     Document Type: Review

References (79)

1. L.K. Newby, I. Rodriguez, and J. Finkle Troponin measurements during drug development-considerations for monitoring and management of potential cardiotoxicity Am Heart J 162 2011 64 73
2. J. Feenstra, D.E. Grobbee, and W.J. Remme Drug-induced heart failure J Am Coll Cardiol 33 1999 1152 1162
3. M. Sonnenblick, and A. Rosin Cardiotoxicity of Interferon. A review of 44 Cases Chest 99 1991 557 561
4. R. Kerkela, L. Grazett, and R. Yacobi Cardiotoxicity of the cancer therapeutic agent imatinib mesylate Nat Med 12 2006 908 916
5. D.B. Merrill, S.E. Ahmari, and J.M.E. Bradford Myocarditis during clozapine treatment Am J Psychiatry 163 2006 204 208
6. P.J. Danaher, M.K. Cao, and G.M. Anstead Reversible dilated cardiomyopathy related to amphotericin B therapy J Antimicrob Chemother 53 2004 115 117
7. M.E. Billingham, M.R. Bristow, and E. Glatstein Adriamycin cardiotoxicity: endomyocardial biopsy evidence of enhancement by irradiation Am J Surg Pathol 1 1977 17 23
8. R.S. Benjamin, J.W. Mason, and M.E. Billingham Cardiac toxicity of adriamycin-DNA complex and rubidazone: evaluation by electrocardiogram and endomyocardial biopsy Cancer Treat Rep 62 1978 935 939
9. M.E. Billingham, J.W. Mason, and M.R. Bristow Anthracycline cardiomyopathy monitored by morphologic changes Cancer Treat Rep 62 6 1978 865 872
10. M.R. Bristow, M.E. Billingham, and J.W. Mason Clinical spectrum of anthracycline antibiotic cardiotoxicity Cancer Treat Rep 62 1978 873 879
11. M.R. Bristow, J.W. Mason, and M.E. Billingham Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization Ann Intern Med 88 1978 168 175
12. M.R. Bristow, P.D. Thompson, and R.P. Martin Early anthracycline cardiotoxicity Am J Med 65 1978 823 832
13. J.W. Mason, M.R. Bristow, and M.E. Billingham Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy Cancer Treat Rep 62 1978 857 864
14. J.W. Mason Anthracycline cardiotoxicity: recognition, management, and avoidance Compr Ther 5 1979 64 68
15. M.R. Bristow, J.W. Mason, and M.E. Billingham Dose-effect and structure-function relationships in doxorubicin cardiomyopathy Am Heart J 102 1981 709 718
16. M.R. Bristow, M.B. Lopez, and J.W. Mason Efficacy and cost of cardiac monitoring in patients receiving doxorubicin Cancer 50 1982 32 41
17. Y. Takeishi, H. Sukekawa, and T. Sakurai Noninvasive identification of anthracycline cardiotoxicity: comparison of 123I-MIBG and 123I-BMIPP imaging Ann Nucl Med 8 1994 177 182
18. M.A. Grenier, and S.E. Lipshultz Epidemiology of anthracycline cardiotoxicity in children and adults Semin Oncol 25 1998 72 85
19. K. Takenaka, Y. Kuwada, and M. Sonoda Anthracycline-induced cardiomyopathies evaluated by tissue Doppler tracking system and strain rate imaging J Cardiol 37 2001 129 132
20. S. Tassan-Mangina, D. Codorean, and M. Metivier Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study Eur J Echocardiogr 7 2006 141 146
21. A. Jannazzo, J. Hoffman, and M. Lutz Monitoring of anthracycline-induced cardiotoxicity Ann Pharmacother 42 2008 99 104
22. D.J. Leishman, T.W. Beck, and N. Dybdal Best practice in the conduct of key nonclinical cardiovascular assessments in drug development: Current recommendations from the Safety Pharmacology Society J Pharmacol Toxicol Methods 65 2012 93 101
23. H.R. Mellor, A.R. Bell, and J.P. Valentin Cardiotoxicity associated with targeting kinase pathways in cancer Toxicol Sci 120 2011 14 32
24. B. Marchandise, E. Schroeder, and A. Bosly Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics Am Heart J 118 1989 92 98
25. G.G. Sandor, M. Puterman, and P. Rogers Early prediction of anthracycline cardiomyopathy using standard M-mode and digitized echocardiography Am J Pediatr Hematol Oncol 14 1992 151 157
26. K. Hanai, K. Takaba, and S. Manabe Evaluation of cardiac function by echocardiography in dogs treated with doxorubicin J Toxicol Sci 21 1996 1 10
27. G. Hanton, M. Gautier, and P. Bonnet Effects of milrinone on echocardiographic parameters after single dose in Beagle dogs and relationship with drug-induced cardiotoxicity Toxicol Lett 155 2005 307 317
28. G. Hanton, M. Gautier, and P. Bonnet Use of M-mode and Doppler echocardiography to investigate the cardiotoxicity of minoxidil in beagle dogs Arch Toxicol 78 2004 40 48
29. A. Casartelli, A. Lanzoni, and R. Comelli A novel and integrated approach for the identification and characterization of drug-induced cardiac toxicity in the dog Toxicol Pathol 39 2011 361 371
30. J.C. Lightfoot, R.B. D'Agostino Jr., and C.A. Hamilton Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model Circ Cardiovasc Imaging 3 2010 550 558
31. M. Bauer, S. Cheng, and M. Jain Echocardiographic speckle-tracking based strain imaging for rapid cardiovascular phenotyping in mice Circ Res 108 2011 908 916
32. M. Tontodonati, N. Fasdelli, and P. Repeto Characterisation of rodent dobutamine echocardiography for preclinical safety pharmacology assessment J Pharmacol Toxicol Methods 64 2011 129 133
33. R.M. Lang, M. Bierig, and R.B. Devereux Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group J Am Soc Echocardiogr 18 2005 1440 1463
34. J.S. Gottdiener, J. Bednarz, and R. Devereux American Society of Echocardiography recommendations for use of echocardiography in clinical trials J Am Soc Echocardiogr 17 2004 1086 1119
35. M. St John Sutton, M.A. Pfeffer, and L. Moye Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial Circulation 96 1997 3294 3299
36. M.G. St John Sutton, T. Plappert, and W.T. Abraham Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure Circulation 107 2003 1985 1990
37. M.G. Sutton, T. Plappert, and K.E. Hilpisch Sustained reverse left ventricular structural remodeling with cardiac resynchronization at one year is a function of etiology: quantitative Doppler echocardiographic evidence from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) Circulation 113 2006 266 272
38. P.S. Douglas, J.M. DeCara, and R.B. Devereux Echocardiographic imaging in clinical trials: American Society of Echocardiography standards for echocardiography core laboratories: endorsed by the American College of Cardiology Foundation J Am Soc Echocardiogr 22 2009 755 765
39. S.F. Nagueh, C.P. Appleton, and T.C. Gillebert Recommendations for the evaluation of left ventricular diastolic function by echocardiography JAm Soc Echocardiogr 22 2009 107 133
40. P.S. Douglas, B. Khandheria, and R.F. Stainback ACCF/ASE/ACEP/ASNC/SCAI/ SCCT/SCMR 2007 appropriateness criteria for transthoracic and transesophageal echocardiography J Am Coll Cardiol 50 2007 187 204
41. FDA. Guidance for Industry: Standards for clinical trial imaging endpoints. Draft Guidance, August 2011. http://www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/ guidances/ucm268555.pdf
42. H. Sawaya, I.A. Sebag, and J.C. Plana Early detection and prediction of cardiotoxicity in chemotherapy-treated patients Am J Cardiol 107 2011 1375 1380
43. M.L. Chuang, M.G. Hibberd, and C.J. Salton Importance of imaging method over imaging modality in noninvasive determination of left ventricular volumes and ejection fraction: assessment by two- and three-dimensional echocardiography and magnetic resonance imaging J Am Coll Cardiol 35 2000 477 484
44. C. Jenkins, S. Moir, and J. Chan Left ventricular volume measurement with echocardiography: a comparison of left ventricular opacification, three-dimensional echocardiography, or both with magnetic resonance imaging Eur Heart J 30 2009 98 106
45. R.M. Lang, W. Tsang, and L. Weinert Valvular heart disease. The value of 3-dimensional echocardiography J Am Coll Cardiol 58 2011 1933 1944
46. D.J. Pennell, U.P. Sechtem, and C.B. Higgins Clinical indications for cardiovascular magnetic resonance (CMR): consensus panel report Eur Heart J 25 2004 1940 1965
47. C. Jenkins, R. Leano, and J. Chan Reconstructed versus real-time 3-dimensional echocardiography: comparison with magnetic resonance imaging J Am Soc Echocardiogr 20 2007 862 868
48. J. Walker, N. Bhullar, and N. Fallah-Rad Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging J Clin Oncol 28 2010 3429 3436
49. F. Grothues, G.C. Smith, and J.C. Moon Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy Am J Cardiol 90 2002 29 34
50. N.G. Bellenger, M.I. Burgess, and S.G. Ray Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J 21 2000 1387 1396
51. A. Pitcher, D. Ashby, and P. Elliott Cardiovascular MRI in clinical trials: expanded applications through novel surrogate endpoints Heart 97 2011 1286 1292
52. W.P. Ingkanisorn, K.L. Rhoads, and A.H. Aletras Gadolinium delayed enhancement cardiovascular magnetic resonance correlates with clinical measures of myocardial infarction J Am Coll Cardiol 43 2004 2253 2259
53. N. Fallah-Rad, M. Lytwyn, and T. Fang Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy J Cardiovasc Magn Reson 10 2008 5
54. P.D. Hockings, A.L. Busza, and J. Byrne Validation of MRI measurement of cardiac output in the dog: the effects of dobutamine and minoxidil Toxicol MechMethods 13 2003 39 43
55. M.Y. Maslov, V.P. Chacko, and G.A. Hirsch Reduced in vivo high-energy phosphates precede adriamycin-induced cardiac dysfunction Am J Physiol Heart Circ Physiol 299 2010 H332 H337
56. M.H. Vandsburger, and F.H. Epstein Emerging MRI methods in translational cardiovascular research J Cardiovasc Transl Res 4 2011 477 492
57. J. Alexander, N. Dainiak, and H.J. Berger Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography N Engl J Med 300 1979 278 283
58. J.L. Ritchie, J.W. Singer, and D. Thorning Anthracycline cardiotoxicity: clinical and pathologic outcomes assessed by radionuclide ejection fraction Cancer 46 1980 1109 1116
59. I. Mitani, D. Jain, and T.M. Joska Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era J Nucl Cardiol 10 2003 132 139
60. I. Shureiqi, S.B. Cantor, and S.M. Lippman Clinical and economic impact of multiple gated acquisition scan monitoring during anthracycline therapy Br J Cancer 86 2002 226 232
61. G.S. Panjrath, and D. Jain Monitoring chemotherapy-induced cardiotoxicity: role of cardiac nuclear imaging J Nucl Cardiol 13 2006 415 426
62. T.F. Chu, M.A. Rupnick, and R. Kerkela Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib Lancet 370 2007 2011 2019
63. E.C. van Dalen, H.J. van der Pal, and W.E. Kok Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study Eur J Cancer 42 2006 3191 3198
64. Z.R. Estabragh, K. Knight, and S.J. Watmough A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib Leuk Res 35 2011 49 51
65. D. Nowis, M. Maczewski, and U. Mackiewicz Cardiotoxicity of the anticancer therapeutic agent bortezomib Am J Pathol 176 2010 2658 2668
66. H. Müller, C. Frangos, and E. Fleury Measurement of left ventricular ejection fraction by real time 3D echocardiography in patients with severe systolic dysfunction: comparison with radionuclide angiography Echocardiography 27 2010 58 63
67. D. Daou, C. Coaguila, and A. Benada Comparison of interstudy reproducibility of equilibrium electrocardiography-gated SPECT radionuclide angiography versus planar radionuclide angiography for the quantification of global left ventricular function J Nucl Cardiol 13 2006 233 243
68. S.T. Palmeri, R.O. Bonow, and C.E. Myers Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography Am J Cardiol 58 1986 607 613
69. Bae JH, Schwaiger M, Mandelkern M, et al. Doxorubicin cardiotoxicity: response of left ventricular ejection fraction to exercise and incidence of regional wall motion abnormalities. Int J Card Imaging 1988-1989;3:193-201.
70. W.I. Ganz, K.S. Sridhar, and T.J. Forness Detection of early anthracycline cardiotoxicity by monitoring the peak filling rate Am J Clin Oncol 16 1993 109 112
71. Y. Cottin, C. Touzery, and B. Coudert Impairment of diastolic function during short-term anthracycline chemotherapy Br Heart J 73 1995 61 64
72. S. Verma, and M.S. Ewer Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer? Ann Oncol 22 2011 1011 1018
73. E. Ho, A. Brown, and P. Barrett Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study Heart 96 2010 701 707
74. R. Ng, N. Better, and M.D. Green Anticancer agents and cardiotoxicity Semin Oncol 33 2006 2 14
75. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 4 http://evs.nci.nih.gov/ftp1/CTCAE/About.html Accessed May 2012
76. Metrics Champion Consortium Central Laboratory Performance Metrics v2.0 http://www.metricschampion.org/Pages/Imaging.aspx Accessed May 2012
77. A.J. Buckler, L.H. Schwartz, and N. Petrick Data sets for the qualification of volumetric CT as a quantitative imaging biomarker in lung cancer Opt Express 18 2010 15267 15282
78. A.J. Buckler, P.D. Mozley, and L. Schwartz Volumetric CT in lung cancer: an example for the qualification of imaging as a biomarker Acad Radiol 17 2010 107 115
79. A.J. Buckler, J.L. Mulshine, and R. Gottlieb The use of volumetric CT as an imaging biomarker in lung cancer Acad Radiol 17 2010 100 106